Mereo BioPharma Group plc (MREO) is a Biotechnology company in the Healthcare sector, currently trading at $0.33. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is MREO = $1 (+153.3% upside).
Valuation: MREO trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Financials: revenue is $500,000, +231.8%/yr average growth. Net income is $42M (loss), growing at -9.9%/yr. Net profit margin is -8375.6% (negative). Gross margin is 73.4% (+35.5 pp trend).
Balance sheet: total debt is $202,000 against $41M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 10.46 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $46M.
Analyst outlook: 5 / 8 analysts rate MREO as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
